Clinical Trials · NCT00891371
Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea
- Phase
- Phase 2/Phase 3
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 42
- Start date
- Jul 2009
- Locations
- 11 sites, Belgium
- Primary endpoint
- Percentage of Patients Having Minimum Reduction of 50% or Normalization (≤3 Stools/24hours) in the Mean Number of Stools (Mean of Last 7 Days)